Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899052 · ClinicalTrials.gov registry record · Phase 2
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2 study of Multiple Myeloma, sponsored by AbbVie.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT02899052 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 120 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT02899052, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Dexamethasone
- DRUG Carfilzomib
Study Locations (20)
Missouri
- Oncology Hematology Associates (OHA) - Springfield /ID# 218855 - Springfield
- Washington University-School of Medicine /ID# 222651 - St Louis
Texas
- University of Texas Southwestern Medical Center /ID# 218336 - Dallas
- Baylor Scott & White Medical Center- Temple /ID# 218252 - Temple
New South Wales
- Border Medical Oncology Research Unit Albury Wodonga Regiona /ID# 222200 - East Albury
- Calvary Mater Newcastle /ID# 218739 - Waratah
Alabama
- University of Alabama at Birmingham - Main /ID# 151405 - Birmingham
Arkansas
- University of Arkansas for Medical Sciences /ID# 151399 - Little Rock
Florida
- Memorial Healthcare System /ID# 224862 - Hollywood
Georgia
- Winship Cancer Institute of Emory University /ID# 161710 - Atlanta
Illinois
- The University of Chicago Medical Center /ID# 151395 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02899052
The ClinicalTrials.gov registry entry for NCT02899052 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT02899052 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Missouri, Texas, New South Wales.
Frequently Asked Questions
What is clinical trial NCT02899052 about?
NCT02899052 is a clinical study titled "Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)". A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.
What is the current status of trial NCT02899052?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2017-01-19. Estimated completion is 2027-06.
What conditions does trial NCT02899052 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02899052?
The interventions under investigation include: Venetoclax (DRUG), Dexamethasone (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT02899052?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02899052 being conducted?
This trial has 20 study locations across Alabama, Arkansas, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.